ImmunityBio, Inc. (NASDAQ: IBRX) has reported a 60% increase in revenue for the second quarter of 2025, totaling $26.4 million, compared to $16.5 million in the first quarter of the same year. Year-to-date sales have reached approximately $43 million. This growth is attributed to the continued commercial traction of ANKTIVA + BCG in treating BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumors. The company also reported a 246% increase in unit sales volume in the first half of 2025 since the J-code approval, compared to the last half of 2024. As of June 30, 2025, ImmunityBio holds $153.7 million in cash, cash equivalents, and marketable securities. In terms of clinical progress, ImmunityBio conducted a Type A meeting with the FDA in June to discuss its program targeting papillary-only non-muscle invasive bladder cancer (NMIBC), following a Refuse-to-File notice in May. The company provided new data demonstrating long-term progression-free survival and bladder sparing with ANKTIVA + BCG. ImmunityBio is considering amending its initial filing with the new data and initiating a randomized controlled trial. Additionally, ImmunityBio has applied to the National Comprehensive Cancer Network to expand BCG-unresponsive NMIBC guidelines to include papillary-only disease. In other developments, ImmunityBio has launched ResQ201A, a randomized controlled trial in the United States for 2nd line lung cancer, evaluating its IL-15 superagonist N-803 in combination with tislelizumab. Clinical trial applications for ResQ201A have been submitted in the European Union and the United Kingdom, with Canada expected in early Q3 2025, and plans are underway to submit in Asia.